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Objective:  The  median  survival  of  leptomeningeal  metastases  is short  despite  therapy  and  is some-
time  associated  with  hydrocephalus.  We  investigated  the  prognostic  signiﬁcance  of  surgically  treated
hydrocephalus  in  leptomeningeal  metastases.
Materials and methods:  Between  December  2005  and  November  2012,  1343  patients  had  brain  metas-
tases  from  systemic  solid  tumors.  Of  these,  71  patients  (5.3%)  experienced  leptomeningeal  metastases
from  45  lung  cancers,  14 breast  cancers,  4 gastric  cancers  and  8 other  cancers.  The  mean  age  was  60
years  (range  37–89).  The  clinical  symptoms  presented  in  the  cerebral  hemisphere  and  cerebellum  in
58  patients,  cranial  nerve  in 7  patients  and  spinal  cord  and  nerves  in  6 patients.  Twenty-nine  (40.8%)
patients  were  Radiation  Therapy  Oncology  Group  recursive  partitioning  analysis  (RTOG-RPA)  class  II  and
42  (59.2%)  were  class  III. Hydrocephalus  was  associated  in  18  (25.4%)  patients  and  7  patients  underwent
ventriculoperioneal  shunt.  The primary  cancer,  clinical  symptoms,  RTOG-RPA  class,  surgically  treated
hydrocephalus  and  systemic  chemotherapy  were  analyzed  as  the  prognostic  factors  for  overall  survival.
Results:  The  overall  incidence  of  leptomeningeal  seeding  was  5.0%  of  the  brain  metastases.  The  median
duration  of  leptomeningeal  metastases  from  ﬁrst brain  metastasis  was  4.0  months  and 24  (33.8%)  patients
showed  leptomeningeal  metastases  as the  ﬁrst  form  of brain  metastasis.  The  median  overall  survival  (OS)
was  2.1  months.  Based  on  the univariate  and  multivariate  analyses,  RTOG-RPA  class  II patients,  treat-
ment  of  leptomeningeal  metastases  (such  as radiotherapy  or  intrathecal  chemotherapy)  and  systemic
chemotherapy  improved  OS  with  statistical  signiﬁcance.  Surgically  untreated  hydrocephalus  (median  OS,
1.7  months)  showed  poor  OS  compared  with  surgically  treated  hydrocephalus  (median  OS,  5.7 months)
and  no hydrocephalus  (median  OS,  2.3  months)  without  statistical  signiﬁcance.
Conclusions: The  leptomeningeal  metastases  were  often  associated  with  hydrocephalus  and  the  surgical
treatment  was  helpful  in limited  patients.  The  prognosis  was  related  with  RTOG-RPA  class  and  treatment
of  local  and  systemic  treatment.. Introduction
Leptomeningeal seeding (LMS) from solid tumors is the result
f seeding of the leptomeninges by cancer. LMS  is also known as
eningeal carcinomatosis, neoplastic meningitis and carcinoma-
ous meningitis. It is diagnosed in around 1–5% of patients with
olid tumors and offers a dismal prognosis [1,2]. The incidence has
 This  is an open-access article distributed under the terms of the Creative Com-
ons Attribution-NonCommercial-No Derivative Works License, which permits
on-commercial use, distribution, and reproduction in any medium, provided the
riginal author and source are credited.
∗ Corresponding author at: Department of Neurosurgery, Chonnam National Uni-
ersity Hwasun Hospital, 160, Ilsim-ri, Hwasun-eup, Hwasun-gun, Jeollanam-do
19-809,  South Korea. Tel.: +82 61 379 7666; fax: +82 61 379 7673.
E-mail  address: jung-ty@chonnam.ac.kr (T.-Y. Jung).
303-8467/$ – see front matter © 2014 The Authors. Published by Elsevier B.V. All rights 
ttp://dx.doi.org/10.1016/j.clineuro.2014.01.023©  2014  The  Authors.  Published  by  Elsevier  B.V. All rights  reserved.
been increasing due to the introduction of diagnostic tools for ear-
lier detection and the therapeutic development for longer survival
[3]. The standard diagnosis of LMS  is the identiﬁcation of malig-
nant cells in cerebrospinal ﬂuid and magnetic resonance imaging
(MRI) plays an important role, even in cytology-negative cases [4,5].
Adenocarcinoma from breast, lung, and melanoma is the frequent
pathology of leptomeningeal metastasis in USA [6,7]. Small cell
lung cancer and melanoma show the higher rates than other solid
cancers [1,7,8].
The  median survival after LMS  is only a few weeks in untreated
patients. LMS  results in signiﬁcant morbidity and short median
survival despite currently available treatment. In this study,
we investigated the prognostic factors related with overall sur-
vival (OS) following leptomeningeal metastases and especially
focused the prognostic signiﬁcance of surgically treated hydro-
cephalus.
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.1.  Clinical characteristics of 71 patients with LMS
One thousand three hundred and forty-three patients had brain
etastases from systemic solid tumors between December 2005
nd November 2012. Of these, 71 patients (5.3%) had LMS. The
nstitutional Review Board of Chonnam National University Hwa-
un Hospital approved this study. The histological diagnosis of the
1 systemic solid tumors were non-small cell lung cancer in 37
atients, small cell lusng cancer in 8, breast cancer in 14, gas-
ric cancers in 4, hepatocellular carcinoma in 2, rectal cancer in 1,
ubmanibular gland cancer in 1, esophageal cancer in 1, gall blad-
er cancer in 1, thymus cancer in 1 and bladder cancer in 1. The
ean age was 60 years (range 37–89). There were 38 males and 33
emales. The synchronous brain metastasis was recognized either
mmediately or within 3 months of the initial diagnosis of primary
ancer and metachronous metastasis was found at a later time. Syn-
hronous metastases of LMS  were evident in 24 patients (33.8%) and
etachronous metastases were detected in 47 patients (66.2%). In
he metachronous metastases, the median duration of LMS  from
he ﬁrst brain metastasis was 4.0 ± 1.0 months. The number of brain
etastases was divided into less than 5 (n = 45, 63.4%), 5–10 (n = 10,
4.1%) and more than 10 (n = 16, 22.5%) on the diagnosis of LMS.
The LMS  was diagnosed based on the magnetic resonance imag-
ng (MRI) of brain and spine with contrast enhancement and/or
he cytology of CSF. The positive MRI  ﬁndings showed the focal or
iffuse contrast enhancement on meninges, ependyma, tentorium,
asal cistern and sulci. Spinal taps were performed for CSF cytology
esting. After cytospin preparations were made, the malignant cells
n CSF deﬁned the positive ﬁnding of LMS. Seventy-one patients
howed positive ﬁndings on brain and/or spine MRI  with contrast
nhancement. The CSF cytology test was done in 23 patients. On the
rst examination, 19 patients (82.6%) out of 23 showed positive
alignant cells and 4 patients (17.4%) showed negative cells. On
epeat CSF exam, two patients with negative cells showed positive
alignant cells.
The  clinical symptoms were classiﬁed in three domains of neu-
ologic function: cerebral hemispheres and cerebellum, cranial
erves and spinal cord and roots. Cerebral hemispheres and cere-
ellum symptoms included headache, nausea/vomiting, seizures,
bnormal gait and mental changes. The symptoms of cranial nerves
ncluded diplopia, visual loss, facial weakness, dysphagia and hear-
ng loss. Symptoms of the spinal cord and roots included back
ain, radiculopathy, myelopathy, paresthesias and paraparesis. The
ain clinical symptoms were presented as signs of cerebral hemi-
phere and cerebellum in 58 patients (81.7%), cranial nerve in 7
atients (9.8%) and spinal cord and nerves in 6 patients (8.5%).
he Radiation Therapy Oncology Group (RTOG) prognostic classes
or brain metastases using a recursive partitioning analysis (RPA)
ased on a three-class system for the future stratiﬁcation and
eporting of brain metastases has been proposed. Class I com-
rises patients with Karnofsky performance status (KPS) ≥70, age
65 years and with controlled primary and no extracranial metas-
ases. Class III patients have KPS <70. Class II patients are all others
9]. Twenty-nine (40.8%) patients showed RTOG-RPA class II and
2 patients (59.2%) class III. Hydrocephalus was associated in 18
25.4%) patients. Seven patients underwent a ventriculoperitoneal
hunt operation. We  placed a pressure adjustable programmable
alve (The CODMAN® HAKIM® Programmable Valve System) in
hree patients and a high pressure valve (The CODMAN® HAKIM®
recision Fixed Pressure Valve) in four patients..2. Statistical methods
OS  was calculated from the date of LMS  until death or until the
atest follow-up. We  deﬁned the median range as the follow-up Neurosurgery 119 (2014) 80–83 81
length  and determined the effects of single variables on OS  via
univariate and/or multivariate analyses. The primary cancer, clini-
cal symptoms, RTOG-RPA classes, surgically treated hydrocephalus,
treatment of LMS  and systemic treatment were analyzed as the
single variables. We  calculated the survival probability using the
Kaplan–Meier method, performing comparisons with the log-rank
test. We examined variables in the proportional hazard analysis
(Cox model) to identify the independent predictors of survival.
All statistical analyses were performed at a signiﬁcance level of
p < 0.05, using the statistical package SPSS 19.0 (SPSS, Chicago, IL).
3.  Results
3.1. Treatment of LMS and systemic cancer
The LMS  patients had been treated using whole brain radiothe-
rapy (WBRT, n = 25), spinal radiotherapy (n = 2), WBRT combined
spinal radiotherapy (n = 4) and intrathecal chemotherapy (n = 2).
The daily fraction of the external bean radiotherapy was  3.0 Gy,
5 days per week. The median total radiation dose was 30 Gy
(range 30–39) for WBRT and 20 Gy (range 18–30) spinal radio-
therapy. Intrathecal chemotherapy was administrated by an
intraventricular Ommaya reservoir in two  patients. Intraven-
tricular methotrexate was  administered at 2 mg per day for 5
consecutive days every other week during 1 month in one patient
and 6 months in one. Systemic chemotherapy for primary cancer
was carried out in 18 patients (25.4%). The pathology was non-small
cell lung cancer in nine patients, breast cancer in six, small cell lung
cancer in two and gastric cancer in one. Thirty-three (46.5%) out
of total 71 patients did not receive any other treatment after LMS
because of a poor clinical condition.
3.2. Prognostic factors related with OS
The median OS was  2.1 ± 0.3 months. Thirteen patients (18.7%)
survived over 6 months and 4 patients (5.7%) over one year.
Univariate analysis revealed an improved OS for the RTOG-RPA
class (p = 0.000, Fig. 1A), treatment of LMS  (p = 0.003, Fig. 1B)
and systemic cancer treatment (p = 0.000, Fig. 1C). There were no
signiﬁcant differences based on primary cancer (p = 0.812), clini-
cal symptoms (p = 0.556) and hydrocephalus (p = 0.404) (Table 1).
RTOG-RPA class II (median OS, 4.6 months; 95% CI, 3.417–5.923)
displayed improved OS compared with class III (median OS, 1.27
months; 95% CI, 0.849–1.691). LMS  treatment including radiothe-
rapy and chemotherapy had an improved OS (median OS, 3.13
months; 95% CI, 2.578–3.682) compared with the no treatment
group (median OS, 1.4 months; 95% CI, 1.122–1.678). Systemic
chemotherapy (median OS, 5.73 months; 95% CI, 3.859–7.601) had
an improved OS compared with the no treatment group (median
OS, 1.5 months; 95% CI, 1.314–1.686).
Multivariate analysis results are summarized in Table 2. RTOG-
RPA class II was signiﬁcantly associated with a longer OS (p = 0.015;
hazard ratio = 0.451; 95% CI, 0.237–0.855) compared to patients
who had III. No LMS  treatment and no systemic treatment
were signiﬁcantly associated with a short OS (p = 0.014; hazard
ratio = 2.024; 95% CI, 1.154–3.550, p = 0.057; hazard ratio = 2.043;
95% CI, 0.979–4.263) compared to patients who had treatments,
respectively.
3.3. Hydrocephalus associated with LMS
Eighteen patients (25.4%) showed the symptomatic hydro-
cephalus associated with LMS. Of these, seven patients (9.9%) were
treated using ventriculoperitoneal shunts. Five patients showed
RTOG-RPA class II and 13 patients class III. Univariate analysis
revealed no signiﬁcant difference of survival based on hydro-
cephalus (p = 0.404). Patients without hydrocephalus had a similar
82 T.-Y. Jung et al. / Clinical Neurology and Neurosurgery 119 (2014) 80–83
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cig. 1. Kaplan–Meier curves relating OS. (A) Patients with RTOG-RPA class II show
mproved OS compared to untreated patients (p = 0.003). (C) Patients receiving syste
D)  Patients with treated hydrocephalus displayed prolonged survival compared to
S (median OS, 2.3 months; 95% CI, 1.482–3.118) compared
ith those with hydrocephalus (median OS, 1.9 months; 95% CI,
.131–2.669). After the ventriculoperitoneal shunt operation, the
atients with untreated hydrocephalus displayed the shortest sur-
ival (median OS, 1.7 months; 95% CI, 0.899–2.561) compared to
he patients without hydrocephalus (median OS, 2.3 months; 95%
I, 1.482–3.118) and the patients with surgically treated hydro-
ephalus (median OS, 5.7 months; 95% CI, 0.000–13.172). However,
here was no the statistical signiﬁcance depending on hydro-
ephalus in all patients (Fig. 1D, p = 0.121). On multivariate analysis,
here was no statistical signiﬁcance between surgically treated and
ntreated hydrocephalus (Table 2).
. Discussion
The prognosis of LMS is poor, with a reported median survival
f untreated LMS  of 4–6 weeks [7]. In our study, median survival in
ntreated LMS  patients was 1.4 months and all LMS  patients was
.1 months. Malignant tumor cells enter the subarachnoid space
nd are transported by CSF, resulting in LMS. These cells reach the
eninges by hematogenous spread, direct extension or along the
erineural or perivascular spaces [10]. The most useful diagnos-
ic test of LMS is examination of CSF [11]. However, false-negative
esults occur in 10–15% of cases. To minimize false-negatives, a
arge sampling volume (>10 cc), prompt processing and repeated
xaminations are necessary. In this study, 82.6% of 23 radiologi-
ally diagnosed patients revealed a positive cytology for malignantproved OS compared with class III (p = 0.000). (B) Patients treated for LMS  showed
reatment showed prolonged survival compared with untreated patients (p = 0.000).
ntreated hydrocephalus. There was no statistical signiﬁcance (p = 0.121).
cells  and a repeat examination elevated the positive result. There-
fore, malignant cells in CSF are diagnostic, but a negative result
cannot rule out LMS. MRI  with gadolinium enhancement is the
diagnostic technique of choice for LMS  and entire CNS evaluation
is considered [12,13]. Enhanced MRI  shows an approximately 30%
incidence of false-negative results [5,14]. However, typical clinical
presentation combined with abnormal MRI  ﬁndings can establish
the diagnosis of LMS, which were the inclusion criteria of patients
in this study. Radiologically, positive MRI  ﬁndings were the focal or
diffuse contrast enhancement on meninges, ependyma, tentorium,
basal cistern and sulci on the brain and spine.
The symptoms and signs of pleomorphic manifestations depend
on the neurologic function of cerebral hemisphere, cerebellum,
cranial nerves and the spinal cord and roots [1,2,6]. The main symp-
toms related with cranial nerve, spinal and radicular nerve more
likely present clinical manifestations due to the LMS, which could
explain their poor outcome. Therefore, we  evaluated OS regarding
clinical symptoms. Even if there was no statistical signiﬁcance
(p = 0.556), the median OS was  2.3 ± 0.5 months for symptoms
of the cerebral hemisphere and cerebellum, 1.9 ± 1.6 months for
symptoms of the spinal cord and roots, and only 1.3 ± 0.9 months
for symptoms of the cranial nerves. The ﬁnding concerning cranial
nerves is consistent with a prior report that patients with cranial
nerve palsies had shorter survival in LMS  patients with intraven-
tricular methotrexate treatment [15].
Treatment of LMS  is complicated. Many factors must be con-
sidered; these include performance status, neurologic deﬁcits and
T.-Y. Jung et al. / Clinical Neurology and
Table  1
Univariate analysis related with OS.
Clinical factors Number (%) p-Value
Primary cancer
Non-small cell lung cancer N  = 37 (52.1%) 0.812
Small cell lung cancer N = 8 (11.3%)
Breast cancer N = 14 (19.7%)
Others N = 12 (16.9%)
Clinical symptoms
Hemisphere and cerebellum N = 58 (81.7%) 0.556
Cranial nerve N = 7 (9.8%)
Spinal cord and roots N  = 6 (8.5%)
RTOG-RPA class
Class  II N = 29 (40.8%) 0.000
Class III N = 42 (59.2%)
Synchronous or metachronous
Synchronous  N = 24 (33.8%) 0.810
Metachronous N = 47 (66.2%)
Number of metastases
<5  N = 45 (63.4%) 0.958
5≤ to < 10 N = 10 (14.1%)
≥10 N = 16 (22.5%)
Hydrocephalus
Yes N = 18 (25.4%) 0.404
No N = 53 (74.6%)
LMS  treatment
No  treatment N = 38 (53.5%) 0.003
Radiotherapy N = 31 (43.7%)
Intrathecal chemotherapy N = 2 (2.8%)
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No  treatment N = 53 (74.6%) 0.000
Systemic chemotherapy N = 18 (25.4%)
ystemic disease [16]. Most treatments require a combination of
alliative steroids, radiotherapy, chemotherapy and surgical treat-
ent of hydrocephalus and large symptomatic mass. Radiotherapy
s used to treat the symptomatic area to relieve symptoms, decrease
he bulky lesion, and correct CSF ﬂow [1,2,6]. The radiotherapy
s still effective, even in patients with signiﬁcant symptoms. The
hole craniospinal irradiation is not recommended for all LMS
atients due to systemic toxicities that include myelosuppression
nd mucositis. In our study, LMS  treatment including radiothe-
apy (median OS, 3.1 months; 95% CI, 2.166–4.034) resulted in
mproved OS compared with the non-treatment group (median OS,
.4 months; 95% CI, 1.122–1.678). For intrathecal chemotherapy,
dministration by Ommaya reservoir could produce more adequate
SF distribution than by lumber puncture [17]. Previous studies
eported median survival of 11.1 and 15.9 weeks after the treatment
f intraventricular methotrexate, respectively [15,18]. In this study,
wo patients received methotrexate chemotherapy by an intraven-
ricular reservoir; a long survival (median 5.7 months) reﬂected the
ood performance status and controllable systemic cancer.
Hydrocephalus in patients with brain metastases is caused by
he obstruction of the CSF pathway from large parenchymal or
ntraventricular mass [19]. The communicating hydrocephalus can
able 2
ultivariate analysis related with OS.
Clinical factors Hazard
ratio
p-Value  95% CI
RTOG-RPA Class II 0.451 0.015 0.237–0.855
LMS treatment No treatment 2.024 0.014 1.154–3.550
Systemic treatment No treatment 2.043 0.057 0.979–4.263
Hydrocephalus No
hydrocephalus
2.060 0.117 0.834–5.090
Untreated
hydrocephalus
0.907 0.860 0.307–2.678
eference: RTOG-RPA Class III, LMS  treatment, systemic treatment, treated hydro-
ephalus.
[
[
[
[
[
[
[
[
[ Neurosurgery 119 (2014) 80–83 83
also developed by LMS. In this study, 18 patients (25.4%) pre-
sented with symptomatic hydrocephalus associated with LMS.
Due to the poor prognosis of LMS, associated hydrocephalus is
sometimes surgically untreated. Therefore, the prognostic signif-
icance of surgically treated hydrocephalus was analyzed in LMS
patients. The patients with surgically untreated and treated hydro-
cephalus showed a median OS of 1.7 months and 5.7 months,
respectively, without the statistical signiﬁcance. Therefore the sur-
gical treatment could be helpful in limited patients. Finally, the
main factors related the OS were RTOG-RPA class, local LMS,
and systemic treatment. When we  surgically treat the hydro-
cephalus in LMS  patients, the functional status and adjuvant local
and systemic treatment could be considered to improve the sur-
vival.
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